2016-10-17T00:00:00-05:00 2015-12-31 521855942 Tate and Tryon 2021 L Street NW Suite 400 Washington DC 20036 990 2015-01-01 133905508 FOOD ALLERGY RESEARCH & EDUCATION INC FOOD 7036913179 7925 JONES BRANCH DRIVE No 1100 MCLEAN VA 221025303 SANDEEP DHAR CFO 7036913179 2016-10-18 1 Elizabeth Heller P00397829 2022932200 2015 2017-02-10 21:41:12Z JAMES BAKER MD 7925 JONES BRANCH DRIVE No 1100 MCLEAN VA 221025303 20371658 0 X WWW.FOODALLERGY.ORG X 1998 NY FARE's mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. 19 18 61 250 44320 0 13080496 12086613 52268 73950 7852 7675829 -312017 -727125 12828599 19109267 1405838 7301480 0 0 6061344 5658318 0 0 2439966 4400863 2998789 11868045 15958587 960554 3150680 9862161 63531340 3301771 6434026 6560390 57097314 X Food Allergy Research & Education (FARE) is the nation's leading advocacy organization working on behalf of the 15 million Americans with food allergies, including all those at risk for life threatening anaphylaxis. FARE's mission is to improve the quality of life and the health of individuals with food allergies, and to provide them hope through the promise of new treatments. Our work is organized around three core tenets: Life - supporting the ability of individuals with food allergies to live safe, productive lives with the respect of others through our education and advocacy initiatives; health - enhancing the access of individuals with food allergies to state-of-the art diagnosis and treatment; and hope - encouraging and fund research in both industry and academia that promises new therapies to improve the everyday lives of those living with food allergies. 0 0 2406965 314457 29630 SEE SCHEDULE OEDUCATION & ADVOCACY:EDUCATION:In 2015, FARE continued to offer world-class food allergy education both nationally at in communities throughout the country. These education efforts are targeted to individuals with food allergies, their families, care givers, public entities that accommodate individuals with food allergies and also the general public. The programs provide vital information, tools and resources on preventing and managing food allergy reactions, including the life-threatening reaction known as anaphylaxis. Additional informational resources provided by FARE in 2015 included the organization's website (foodallergy.org), blog, and social media channels. FARE continued to offer its ongoing monthly webinar series on a variety of topics related to food allergy management, and distributed key educational materials such as "Your Food Allergy Field Guide," a comprehensive resource for newly diagnosed patients through physician offices and direct to patients. FARE hosted its annual Teen Summit, a national gathering of teens (ages 11-22) with food allergies, along with their parents and siblings, and in doing so set a new GUINNESS WORLD RECORDS title achievement for the "Largest Allergy Awareness Lesson." FARE's National Food Allergy Conference and Leaders' Summit, held in May, brought together individuals and families managing food allergies, caregivers, school staff, and health care professionals, giving them an opportunity to learn about advances in food allergy research and advocacy, best practices and practical skills for living well with food allergies. The organization also hosted the annual International Food Allergy Alliance Meeting, which gathers leaders from patient advocacy organizations across the world to guide international policy on food allergy research, education and treatment, advance food allergy awareness, and encourage the commercial sector to support the food allergy community.Also in 2015, FARE launched the pilot phase of its college program initiative, providing hands-on training and audits with 12 colleges and university across the country and offsetting costs for an additional 41 schools through a training grant program.FARE also continued its national training programs for restaurant workers on serving diners with food allergies and also continued the expansion for the SafeFARE website, a resource for the hospitality industry and diners with food allergy. For the management of food allergy in schools, FARE continued managing a cooperative agreement with the CDC where we created user-friendly resources, tools and webinars based on the CDC's Voluntary Guidelines for Managing Food Allergies in Schools and Early Care and Education Programs.FARE also provided $143,000 in community funding awards to local food allergy advocates and leaders to support education and awareness programs in their local communities. These awards served a total of nearly 1 million people across 50 communities in 25 states. In partnership with Children's National Health System in Washington DC, FARE also began work on a pilot project to support underserved communities in receiving accurate food allergy diagnosis and appropriate follow-up care.ADVOCACY:FARE devoted resources to addressing a range of public policy issues that affect Americans with food allergies and the entities that serve them. FARE continued to provide information and subject matter expertise to the Food and Drug Administration and National Institutes of Health, helped initiate and continued to serve as a leading resource for a consensus panel on food allergy at the Institute of Medicine, worked to improve allergen labeling and manufacturing practices, and spearheaded the introduction of a bill in Congress that would improve the safety of people with food allergies who travel on airlines. At the state level, FARE has been integral to the passage of laws that allow or require schools to stock auto-injectable epinephrine in 48 states, as well as 19 states that now allow public-serving entities to stock this lifesaving medication as well. FARE continued its collaborative efforts with allied professionals by presenting at conferences and working on projects with the National Confectioners Association, the Association of Food and Drug Officials, the Institute for Food Safety and Health, the Conference for Food Protection, and others. 2273704 SEE SCHEDULE OAWARENESS:Through its educational programs, community activities, fundraising efforts, and outreach to media nationwide, FARE heightens awareness of food allergy as a significant and growing public health issue that demands urgent attention. In 2015, FARE's national FARE Walk for Food Allergy program brought together supporters in nearly 60 communities for family-friendly events focused on supporting the food allergy community's cause and increasing awareness of food allergy as a serious public health issue. In May 2015, FARE once again launched its Food Allergy Action Month campaign, which expands the traditional awareness week into an entire month of activities and actions supporters can take to help increase understanding of food allergies and make a positive difference in the lives of those managing the disease. In October 2015, FARE raised awareness about food allergies via its high-profile campaign, the Teal Pumpkin Project, designed to promote safety, inclusion and respect of individuals managing food allergies - and to keep Halloween a fun, positive experience for all. Resonating with communities across the country and around the world, the Teal Pumpkin Project reached 6.5 million users on Facebook, more than half a million people on Twitter, was covered by hundreds of media outlets, and garnered participation from all 50 states, Washington, D.C., Puerto Rico and in 14 countries. FARE received coverage in more than 1,000 media outlets throughout the year. In the digital space, FARE's award-winning website and blog received more than 3.5 million visits in 2015, FARE's bimonthly e-newsletter reached nearly 150,000 subscribers with each edition, and FARE's growing social media presence reached millions of users with important information about food allergies and FARE programs. In 2015, FARE issued 195 allergy alerts, which provide information about mislabeled or recalled food, and 17 ingredient notices, which are advance notifications of ingredient changes from food companies. For food allergy families, this is critical information to receive in order to prevent inadvertent reactions. 8046776 6987023 SEE SCHEDULE ORESEARCH:FARE Clinical NetworkThe cornerstone of FARE's research commitment in 2015 was the launch of the FARE Clinical Network ('FCN') with 24 centers of excellence across the United States. The FCN sites are changing the face of food allergy research by raising the quality of care for food allergic patients nationwide, by reducing discrepancies in care among providers, and by making comprehensive care available for all patients with food allergies. FCN sites are helping parents, caregivers and patients identify centers that provide clinical and sub-specialty food allergy services of the highest quality and that are leaders in rapidly applying new evidence-based knowledge. Importantly, FCN centers are accelerating drug development for food allergy by enhancing sites' infrastructure and capabilities to perform crucial late stage trials and providing the basis for a national food allergy patient registry and bio-repositories. New Investigator and Mid-Career AwardsFARE is also committed to markedly increasing the number of investigators in the field through its FARE Investigator in Food Allergy Award Program that was launched in 2015. The Program is divided into two categories: New Investigator Awards and Mid-Career Awards. FARE awarded two grants in the former and three grants in the latter for a total commitment of up to $2.55mm.New Investigator Recipients ($75K annually for 2 years)1. Jessica O'Konek, PhD, University of Michigan (Ann Arbor) - O'Konek will research the modulation of food allergy responses with nanoemulsion-based allergy vaccines, exploring the possibility of providing protection against anaphylaxis with intranasal administration of nanoemulsion combined with egg or peanut antigens. 2. Duane Wesemann, MD, PhD, Brigham and Women's Hospital (Boston) - Wesemann seeks to identify the extent to which primary Ig repertoires can be influenced by microbial and dietary exposures early in life and examine how modification of these exposures can reduce allergic response to food. Mid-Career Award Recipients ($150K annually for 5 years)1. Simon Hogan, PhD, Cincinnati Children's - Hogan's work focuses on identifying the key proteins and cells that cause the blood vessel fluid leak leading to severe anaphylaxis triggered by foods. This knowledge will have important implications for developing new treatment strategies and therapeutics for preventing the development of severe, life-threatening food reactions. 2. Michiko Oyoshi, PhD, Boston Children's Hospital and Harvard Medical School - Oyoshi will examine the role of maternal antibodies transferred to babies through breast milk in inducing oral tolerance in children. This study may support potential beneficial effects of maternal allergen exposure during pregnancy and lactation on protecting babies from food allergy. 3. Erik Wambre, PhD, Benaroya Research Institute (Seattle) - Wambre will investigate the specific T cell responses to peanut allergic components to determine the cellular and molecular mechanism associated with peanut sensitization, as well as those that lead to restoration and maintenance of protective responses. FARE also supports established researchers through funding basic, clinical and epidemiological research at a number of sites across the country. FARE continued its support of the following research studies in 2015 that had been approved in prior years. FARE's Research Advisory Board (RAB) monitors progress relative to milestones closely for all grant awards.1. FARE is a lead funder of a study from a committee of the Health & Medicine Division of the National Academies of Science, Engineering and Medicine (formerly the Institute of Medicine) entitled Food Allergy: Global Burden, Causes, Treatment, Prevention and Public Policy. The Committee has provided quarterly updates and convened meetings to provide updates on the study and timing of the final report which is currently planned for release in Q4 of 2016. 2. Edwin Kim, MD - U. North CarolinaSecond Site: U. Texas Southwest (Drew Bird, MD)Study: Peanut Sublingual Immunotherapy (SLIT) TrialThe long-term objective of this study is to develop a safe and effective treatment for peanut allergy that will enable patients to develop tolerance with the hope that this study will provide a strong scientific basis for the development of SLIT and other treatments that aim to produce long-term clinical tolerance to peanuts and other foods. This study is also being conducted at UT Southwestern Medical Center in Dallas. Status: Recruitment ongoing.3. Fred D. Finkelman, McDonald Professor of Medicine, Professor of Pediatrics, U. of Cincinnati College of Medicine Study: Rapid Suppression of Food Allergy with Anti-FCeRIa Antibody Summary: Dr. Finkelman's group at the University of Cincinnati and Cincinnati Children's Hospital published a paper in the June, 2013 issue of the JACI that describes a novel approach for suppressing IgE-mediated allergy: rapid desensitization with an antibody to the high affinity IgE receptor, Fc epsilon RI. The paper showed that this approach could completely suppress IgE-mediated anaphylaxis in mice and that it was longer lasting and less likely to be associated with side effects than rapid desensitization with an allergen. The goal of this proposal is to adapt this approach to people who have IgE-mediated disease, on making it work more rapidly (hours instead of days) and on making it even safer. 4. Dr. Ruchi Gupta - Lurie Children's Hospital of Chicago Study: Understanding Differences in Knowledge and Attitudes Around Food Allergy Thresholds and FoodStatus: Project Completed and submitted for publication in academic journals.5. Dr. Ruchi Gupta - Lurie Children's Hospital of ChicagoStudy: Understanding Global Practices Around Food Allergy Labeling Laws in US & CanadaThe goal of this study is, to improve understanding of the knowledge around food allergy labeling laws and purchasing practices of food products with advisory statements in the U.S. and Canada.Status: Project Completed and submitted in academic journals for publication.In addition, FARE continued to fund ongoing clinical trials (Peanut OIT with Xolair, Wheat, Walnut OIT), of promising new treatments, as well as epidemiological and basic research.The results of FARE-funded research studies were published in leading peer-reviewed scientific journals, including Allergy & Asthma Proceedings, Annals of Allergy and Immunology, JAMA Pediatrics, the Journal of Allergy and Clinical Immunology, and the Journal of Allergy and Clinical Immunology: In Practice. Specifically, the results of the following FARE-funded research studies were presented at 1Q 2015 AAAAI meeting: 1. The LEAP Study (Dr. Gideon Lack - Kings College, London, see below); and 2) Milk OIT and Xolair Study (Dr. Hugh Sampson, Mount Sinai School of Medicine) Gideon Lack, MD King's College London, UKTolerance to peanut in high-risk children (LEAP Study)The LEAP (for "Learning Early About Peanut Allergy") study was primarily co-funded by the National Institutes of Health (NIH) and FARE. The results of this study, published in February 2015 in the New England Journal of Medicine, showed that sustained consumption of a peanut-containing snack by babies at high risk for developing peanut allergy prevented them from developing peanut allergy. Led by Dr. Gideon Lack of Kings College London, researchers tested the hypothesis that foods containing peanut - if started during the first year of life - could elicit a protective immune response rather than an allergic reaction.Hugh Sampson, MDIcahn School of MedicineMilk OIT with Xolair StudyThis study was funded by the NIAID and a supplemental grant from FARE. The results of this study showed that combining omalizumab (Xolair) with milk oral immunotherapy (OIT) makes treatment significantly safer, but does not increase the efficacy of OIT, according to findings by a team of researchers from the Johns Hopkins University School of Medicine, Stanford University and the Icahn School of Medicine at Mount Sinai.Xiaobin Wang, MDJohns Hopkins Bloomberg School of Public HealthEpigenetic StudyFunded by the NIAID, FARE, and the Bunning family and their family foundationThe researchers pinpointed a region in the human genome associated with peanut allergy in U.S. children, offering strong evidence that genes can play a role in the development of food allergies.But additional findings that suggests genes are not the only players in food allergies, and the research team found there may be other molecular mechanisms that may contribute to whether those who are genetically predisposed to peanut allergies actually develop them. 12727445 1 1 0 1 0 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 58 0 1 61 1 1 1 0 0 0 0 1 1 0 0 0 0 X 19 18 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC UT VA WA WV WI X X SANDEEP DHAR 7036913179 7925 JONES BRANCH DRIVE SUITE 1100 MCLEAN VA 22102 Janet Atwater Chair 1.00 X X 0 0 0 Rob Nichols Vice-Chair 1.00 X X 0 0 0 Mike Lade Treasurer 1.00 X X 0 0 0 Sharyn Mann Secretary 1.00 X X 0 0 0 Maria Acebal Director 1.00 X 0 0 0 Julia Birkey Director 1.00 X 0 0 0 David Crown Director 1.00 X 0 0 0 Rachael Dedman Director 1.00 X 0 0 0 Andy Gilman Director 1.00 X 0 0 0 John Hannan Director 1.00 X 0 0 0 Joe Ianniello Director 1.00 X 0 0 0 David Jaffe Director 1.00 X 0 0 0 Rebecca Lainovic Director 1.00 X 0 0 0 Adam Miller Director 1.00 X 0 0 0 Amie Rappoport-McKenna Director 1.00 X 0 0 0 Joelle Resnick Director 1.00 X 0 0 0 Todd Slotkin Director 1.00 X 0 0 0 Mary Weiser Director 1.00 X 0 0 0 James R Baker CEO, CMO 40.00 X X 496768 0 39043 Sandeep Dhar CFO 40.00 X 185177 0 5540 Mary Jane Marchisotto Sr. VP Research 40.00 X 242876 0 10644 Donna McKelvey Sr. VP Development 40.00 X 229186 0 6038 Veronica LaFemina VP Communications 40.00 X 154832 0 12465 Scott Riccio Sr. VP Education and Advocacy 40.00 X 260302 0 20574 Lanny BROMFIELD Controller 40.00 X 137482 0 14285 John Lehr Former CEO 0.00 X 186813 0 0 1893436 0 108589 8 1 1 0 University of North Carolina DEPT of Pediatrics Chapel Hill NC 27599 Allergy Research 291917 Boston Children's Hospital 300 Longwood Avenue Boston MA 02115 Allergy Research 210000 ColorNet Printing & Graphics 22570 Glenn Dr Sterling VA 20164 Copy & Printing 132686 MenuTrinfo LLC 155 North College Ave Suite 200 Fort Collins CO 80524 Manager Training program 127888 Dataprise Inc PO BOX 62550 Baltimore MD 21264 IT service 116768 12 148850 4619475 168769 7149519 12086613 Advertising 541800 44320 44320 EDUCATIONAL PROGRAMS 900099 29630 29630 73950 14577 14577 11270 0 11270 11270 11270 7712415 51163 7661252 7661252 7661252 341549 4619475 1129746 -788197 -788197 55890 42635 13255 13255 61013 38847 22166 22166 OTHER INCOME 900099 14381 14381 14381 19109267 51796 44320 6926538 7295210 7295210 6270 6270 1858250 1254851 156958 446441 3034986 2053712 255614 725660 93187 62246 7860 23081 334069 213517 30668 89884 337826 224577 29995 83254 155667 155667 32967 9291 20646 3030 36850 36850 94125 94125 585633 417211 1952 166470 54648 7715 46933 459458 188714 17739 253005 377683 201182 68216 108285 470088 251633 101696 116759 377775 273362 29614 74799 43942 22135 12753 9054 60575 30514 17580 12481 bank fees 201486 110880 2626 87980 Mail Shop Fees 42475 7910 34565 MISC. EXPENSES 5417 2390 409 2618 15958587 12727445 791176 2439966 X 2115012 1372489 0 742523 1751322 3035347 3762810 11421870 3548389 1310369 105820 30630 45538 24230 365663 95778 209353 111369 88971 97984 150505 47485577 43143 29555 9862161 63531340 627365 708490 2529250 5604373 3449 141707 121163 3301771 6434026 X 1609829 52302888 4950561 4794426 6560390 57097314 9862161 63531340 3150680 47386244 0 X 0 1 X 1 0 X 7361212 8817983 15724060 13005978 12086613 56995846 7361212 8817983 15724060 13005978 12086613 56995846 11709752 45286094 18160 24100 15222 7932 25847 91261 57087107 513733 0.79330 0.73290 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 94125 94125 17079473 17173598 1000000 250000 0 0 640608 779300 739676 1000000 3159584 4739376 506841 321000 152250 94125 1074216 160152 194825 184919 250000 789896 1184844 16547 8589 7958 179276 91953 87323 13530 10827 2703 97984 INVESTMENT IN AIMMUNE THERAPEUTICS, INC. (AIMT) 47485577 F 47485577 DEFERRED RENT 121163 121163 67814700 47386244 107961 1211229 48705434 19109266 0 19109266 17277776 107961 1211229 1319190 15958586 0 15958586 Part XI, Line 2d - Other Adjustments: COST OF GOODS SOLD 38,847. DIRECT FUNDRAISING EXPENSES 1,172,382. Part XII, Line 2d - Other Adjustments: COST OF GOODS SOLD 38,847. DIRECT FUNDRAISING EXPENSES 1,172,382. GALA 2818668 2633339 185329 23331 15000 255876 216029 LUNCH 881297 881297 19820 26225 124618 124594 3 1261059 1104839 156220 30649 13395 140730 18000 121479 4961024 4619475 341549 73800 54620 521224 18000 462102 1129746 -788197 55890 42635 1 0.85000 55890 42635 42635 13255 NY 1 0 1 0 1.00000 ANNE HORNING 515 MADISON AVENUE SUITE 1912 NEW YORK NY 10022 0 0 1 Icahn School Of Medicine at Mount Sinai Box 1198 One Gustave L Levy Place New York NY 100296574 136171197 501 ( c ) 3 61809 Research Lurie Children's Hospital of Chicago - FACE Program 225 E Chicago Ave Chicago IL 60611 362170833 501 ( c ) 3 23000 Research Icahn School Of Medicine Box 1198 One Gustave L Levy Place New York NY 100296574 136171197 501 ( c ) 3 60000 Research University of N Carolina 104 Airport Dr suite 2200 Chapel Hill NC 27599 561118388 501 ( c ) 3 1601775 Peanut Sublingual Immunotherapy Trial University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 753209906 756002868 501 ( c ) 3 266652 Peanut Sublingual Immunotherapy Trial Johns Hopkins Children's center 750 E Pratt Street Baltimore MD 21202 520595110 501 ( c ) 3 10000 Research Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 981012795 910653422 501 ( c ) 3 750000 Correlation Between Peanut Specific CD4+ T Cell Responses and Clinical Statu Arkansas Children's Hosp Research Institute 13 Childrens Way Little Rock AR 72202 710694931 501 ( c ) 3 120000 Peanut Sublingual Immunotherapy induction of Clinical Tolerance Boston Children's Hospital 300 Longwood Avenue Boston MA 02115 042774441 501 ( c ) 3 750000 Induction of Neonatal Tolerance Through Breast Milk Boston Children Hospital 300 Longwood Avenue Boston MA 02115 042774441 501 ( c ) 3 120000 FARE Clinical Network The Brigham & Women's Hospital Research Management Boston MA 02115 042312909 501 ( c ) 3 150000 Deciphering Environmental B Cell Tolerance at he Gut Mucosa Children's Hospital of Pittsburgh of UPM 4401 Penn Avenue Pittsburgh PA 152241334 250402510 501 ( c ) 3 120000 FARE Clinical Network Cincinnati Children's Hospital Medical Center 3333 Burnet Avem ML 7030 Cincinnati OH 452293039 310833936 501 ( c ) 3 750000 Vascular Endothelium-C-Abi Kinase Axis Underpins the Onset of a Severe Food- Cincinnati Children's Hospital Medical Center 3333 Burnet Avem ML 7030 Cincinnati OH 452293039 310833936 501 ( c ) 3 120000 FARE Clinical Network Ann&Roberth H Lurie Children's Hospital of Chicago 225 E Chicago Ave Chicago IL 60611 362170833 501 ( c ) 3 120000 FARE Clinical Network Massachusetts General Hospital 175 Cambridge Street Boston MA 02114 042697983 501 ( c ) 3 120000 FARE Clinical Network National Jewish Health 1400 Jackson Street Denver CO 80206 742044647 501 ( c ) 3 120000 FARE Clinical Network Rady Children's Hospital University of California 9500 Gilman Drive 0934 La Jolla CA 92093 956006144 501 ( c ) 3 120000 FARE Clinical Network The Children's Hospital of Philadelphia 3401 Civic Center Blvd Philadelphia PA 19104 231352166 501 ( c ) 3 120000 FARE Clinical Network University of North Carolina 260 MacNider CB7220 Chapel Hill NC 27599 566001393 501 ( c ) 3 120000 FARE Clinical Network University of Arizona PO Box 210017 Tuscon AZ 85721 742652689 501 ( c ) 3 70000 FARE Clinical Network Indiana University 11725 N Illinois Street Carmel IN 46032 356001673 501 ( c ) 3 70000 FARE Clinical Network Northwest Allergy and Ashma 9725 3rd Ave NE Suite 500 Seattle WA 98115 237219813 501 ( c ) 3 70000 FARE Clinical Network University of Chicago 5801 S Ellis Ave Chicago IL 60637 362177139 501 ( c ) 3 70000 FARE Clinical Network Children's National Medical Center 111 Michigan Ave NW Washington DC 20010 521640403 501 ( c ) 3 70000 FARE Clinical Network Baylor College of Medicine 1 baylor Plaza Houston TX 77030 741613878 501 ( c ) 3 70000 FARE Clinical Network Children's Mercy Hospital 2401 Gillham Rd Kansas City MO 64108 440605373 501 ( c ) 3 70000 FARE Clinical Network University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 75235 756002868 501 ( c ) 3 120000 FARE Clinical Network Icahn School of Medicine Box 1198 One Gustave L Levy Place New York NY 100296574 136171197 501 ( c ) 3 120000 FARE Clinical Network Joe Dimaggio Children's Hospital 3501 Johnson St Hollywood FL 33021 596014973 501 ( c ) 3 70000 FARE Clinical Network Stanford University-FCN 2015-05-015 3160 Porter Drive Palo Alto CA 94304 911156365 501 ( c ) 3 155494 FARE Clinical Network University OF Michigan-NI2015-06-001 500 S State St Ann Arbor MI 48109 386006309 501 ( c ) 3 150000 Modulation of Food Allergy Responses with Nanoemulsion-based Allergy Vaccine University of California 110000 Kinross Avenue Suite 211 Los Angeles CA 90095 956006143 501 ( c ) 3 70000 FARE Clinical Network university of Colorado Mail Stop F428 Aurora CO 80045 846000555 501 ( c ) 3 120000 FARE Clinical Network Regents of the University of Michigan 500 S State St Ann Arbor MI 48109 386006309 501 ( c ) 3 58334 FARE Clinical Network AllergyImmunology Department Children's Hospital Of Pittsburgh of UPMC 4401 Penn Avenue Pittsburgh PA 152241334 250402510 501 ( c ) 3 8080 Education Grant Food Allergy Support Group of Tidewater 1800 Buttermilk Ct Virginia Beach VA 23456 383775800 501 ( c ) 3 7062 Education Grant Lakota Nutrition 6947 Yankee Rd Liberty Township OH 45011 263592983 501 ( c ) 3 7000 Education Grant Organization for Autism Research 2000 14th St N Suite 240 Arlington VA 22201 542062167 501 ( c ) 3 193322 Education Grant Utah Food Allergy Network PO Box 711246 Salt Lake City UT 84171 208914771 501 ( c ) 3 6100 Education Grant Washington FEAST 8305 31st St Ave NW Seattle WA 98117 262003207 501 ( c ) 3 6150 Education Grant 34 EDUCATION 1 6270 Part I, Line 2: THERE IS A FORMAL GRANT REVIEW PROCESS. ALL DISBURSEMENTS ARE DOCUMENTED. GRANTEES ARE REQUIRED TO WRITE ANNUAL UPDATES ON THEIR PROGRESS AS WELL AS GOALS ACHIEVED. FUTURE GRANT AWARDS ARE CONTINGENT UPON ACHIEVEMENT OF SPECIFIC MILESTONES. X X X 1 0 0 0 0 0 0 1 0 James R Baker CEO, CMO 494788 0 0 0 1980 0 15000 0 25517 0 537285 0 0 0 Sandeep Dhar CFO 184659 0 0 0 518 0 5540 0 1132 0 191849 0 0 0 Mary Jane Marchisotto Sr. VP Research 230896 0 10000 0 1980 0 7357 0 5014 0 255247 0 0 0 Donna McKelvey Sr. VP Development 210000 0 10000 0 9186 0 6038 0 1467 0 236691 0 0 0 Veronica LaFemina VP Communications 144592 0 10000 0 240 0 4540 0 9134 0 168506 0 0 0 Scott Riccio Sr. VP Education and Advocacy 160102 0 0 0 100200 0 4950 0 16609 0 281861 0 0 0 Lanny BROMFIELD Controller 125088 0 5000 0 7394 0 4029 0 11246 0 152757 0 0 0 John Lehr Former CEO 0 0 0 0 186813 0 0 0 0 0 186813 0 0 0 Part I, Line 7 BONUSES ARE PROVIDED TO ENSURE THAT KEY EMPLOYEES WHO PERFORM WELL ARE RECOGNIZED FOR THEIR PERFORMANCE AND RETAINED BY FARE. THE PERFORMANCE OF THESE EMPLOYEES WAS REVIEWED BY MANAGEMENT, INCLUDING THE CEO, AND BONUSES WERE AWARDED APPROPRIATELY. OTHER REPORTABLE COMPENSATION INCLUDES SEVERANCE PAY, RELOCATION, AND TRANSITION COSTS. Part I, Line 4a John Lehr, Former CEO, was paid $186,813 in severance pay during 2015. X FASHION/BEAUTY PACKAGES 59 26119 FMV X VACATION PACKAGES 4 5791 FMV X OTHER MISCELLANEOUS 8 4849 FMV X FITNESS/GYM 12 4744 FMV X SPORTS/SHOWS 3 603 FMV X FOOD/RESTAURANT GIFT CERT 2 530 FMV 0 0 0 0 Form 990, Part VI, Section B, line 11 a DRAFT OF FORM 990 IS SENT TO THE BOARD FOR REVIEW BEFORE IT IS FILED WITH THE IRS. Form 990, Part VI, Section B, line 12c ALL STAFF, BOARD MEMBERS, OFFICERS AND TRUSTEES ANNUALLY SIGN A FOOD ALLERGY RESEARCH & EDUCATION MANAGEMENT AND STAFF DISCLOSURE STATEMENT WHICH AFFIRMS THAT THEY HAVE RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY, HAVE READ AND UNDERSTAND IT, AND HAVE AGREED TO COMPLY WITH THE POLICY. IF A CONFLICT OF INTEREST IS DISCLOSED, THE AFFECTED PARTY WILL DISCUSS THE ISSUE WITH THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS WILL DISCUSS THE ISSUES, CONSULT AN ATTORNEY IF NECESSARY, AND TAKE APPROPRIATE ACTION. APPROPRIATE DISCIPLINARY ACTION WILL BE IMPOSED AGAINST ANY PERSON VIOLATING THE POLICY. Form 990, Part VI, Section B, line 15 THE ORGANIZATION USES COMPARABLE DATA IN THE INDUSTRY TO DETERMINE COMPENSATION AND COMPENSATION IS VOTED AND AGREED UPON BY THE GOVERNING BODY. Form 990, Part VI, Section C, line 19 THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. ANY OTHER DOCUMENTS ARE AVAILABLE UPON REQUEST.